Fig. 1
Flowchart showing the distribution of the study population. IVR, intravitreal ranibizumab; IVC, intravitreal conbercept; PPV, pars plana vitrectomy
Fig. 1 | Eye and Vision
Flowchart showing the distribution of the study population. IVR, intravitreal ranibizumab; IVC, intravitreal conbercept; PPV, pars plana vitrectomy
Eye and Vision